Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Dados básicos

Código:
Estudo Observacional Académico (4WARD)
Protocolo:
Estudo Observacional Académico (4WARD)
EUDRACT:
NCT:
Centro:
Dotação:
Ano de início:
2021
Ano de conclusão:
Estudos observacionais Nacional Não Financiado Outros

Objectivos do projeto

Tipo de Estudo: Estudo Observacional – Iniciativa do Investigador; Subtipo: Outro; Fase: Cross-sectional; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Unicêntrico - Cuidados Secundários - Centros de Ensaio: CHUSJ - Doença investigada: Doença Inflamatória Intestinal – Participantes recrutados: 30;

Documentos

  • Não há documentos

Participantes

Unidades de investigação

Stakeholders - Promotores

FMUP

Outputs do ensaio clínico


A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes

Estevinho, Maria Manuela; (...); Magro, Fernando

Review. 10.1177/17562848221142673. 2022

  • Open Access.

A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective study

Magro, F.; (...); Dias, C. C.

Meeting Abstract. 2023


Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines

Farrugia, Y.; (...); Ellul, P.

Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024


Active pharmacovigilance project in a tertiary hospital

Souto, Miguel Torre; (...); Reina-Couto, Marta

Meeting Abstract. 2023


Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

Magro, F.; (...); Feagan, B. G.

Meeting Abstract. 2023


ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Magro, FERNANDO; (...); Feagan, Brian G.

Meeting Abstract. 2023


Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study

Abreu, C; (...); Magro, F

Article. 10.3390/vaccines11030703. 2023

  • Open Access.

Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study.

Abreu, C; (...); Magro, F

Article. 2023


Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?

Ministro, P; (...); Magro, F.

Article. 10.14309/ctg.0000000000000309. 2021

  • Open Access.

Aminosalicylates and COVID-19: Facts or Coincidences?

Magro, F., Dias, C., Morato, M.

Letter. 10.1053/j.gastro.2020.05.092. 2021

  • Open Access.

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

D'Amico, Ferdinando; (...); Allocca, Mariangela

Article. 10.1111/eci.14283. 2024

  • Open Access.

Analysis of clinical features associated with favourable outcomes from ustekinumab treat-totarget strategy in Crohn's Disease patients in the STARDUST trial

Danese, S; (...); Peyrin-Biroulet, L

Meeting Abstract. 10.1093/ecco-jcc/jjab075.039. 2021

  • Open Access.

Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis

Ferreira Duarte, M; (...); Morato, M

Article. 10.1111/jgh.16541. 2024

  • Open Access.

Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations

Schreiber, S. W.; (...); Peyrin-Biroulet, L.

Meeting Abstract. 2023


Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program

Dubinsky, Marla C.; (...); Regueiro, Miguel

Article. 10.1093/ibd/izac061. 2023

  • Open Access.

Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review

Gomes, SF; (...); Magro, F

Review. 10.3390/ijms252312852. 2024

  • Open Access.

Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease

Magro, F.; (...); Reinisch, W.

Meeting Abstract. 2022


ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Magro, FERNANDO; (...); Reinisch, Walter

Meeting Abstract. 10.1136/gutjnl-2022-BSG.74. 2022


Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''

Sousa, Paula, Magro, Fernando

Editorial Material. 10.1016/j.dld.2023.12.006. 2024


Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

Gisbert, Javier P.; (...); Vermeire, Severine

Article. 10.1093/ibd/izae162. 2024

  • Open Access.

Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study

Gisbert, J. P.; (...); Vermeire, S.

Meeting Abstract. 2024


Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties

Couto, MR; (...); Martel, F.

Article. 10.1016/j.yexcr.2023.113670. 2023

  • Open Access.

Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus

D'Amico, F; (...); Danese, S

Review. 10.1016/j.autrev.2021.102849. 2021

  • Open Access.

Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal

Magro, F.; (...); Correia, L.

Meeting Abstract. 2021


Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal

Magro, FERNANDO; (...); Correia, Luis

Article. 10.1159/000525206. 2023

  • Open Access.

CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

Peyrin-Biroulet, Laurent; (...); Danese, Silvio

Meeting Abstract. 2022


CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Danese, Silvio; (...); Peyrin-Biroulet, Laurent

Meeting Abstract. 2021


Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST

Peyrin-Biroulet, Laurent; (...); Danese, Silvio

Article. 10.1111/apt.17751. 2024

  • Open Access.

Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine

Borges-Carneiro, Filipa; (...); Magro, FERNANDO

Editorial Material. 10.20344/amp.21371. 2024

  • Open Access.

Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis

Magro, F; (...); Peyrin-Biroulet, L

Review. 10.1093/ecco-jcc/jjaa176. 2021

  • Open Access.

Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis (vol 15, pg 551, 2021)

Vermeire, Severine; (...); Danese, Silvio

Correction. 2021


Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Allocca, Mariangela; (...); Fiorino, Gionata

Article. 10.1002/ueg2.12492. 2024

  • Open Access.

Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies

Estevinho, M. M.; (...); Magro, F.

Meeting Abstract. 2022


Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis

Magro, F; (...); Moreira, PL

Review. 10.1177/17562848221092754. 2022

  • Open Access.

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis

Magro, F; (...); Moreira, P

Review. 10.1002/ueg2.12183. 2022

  • Open Access.

CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

Ma, C; (...); Jairath, V

Article. 10.1053/j.gastro.2022.06.068. 2022

  • Open Access.

COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology

Magro, F.; (...); Siau, K

Review. 10.1002/ueg2.12115. 2021

  • Open Access.

COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives

Magro, Fernando, Estevinho, Maria Manuela

Editorial Material. 10.1093/ecco-jcc/jjac042. 2022

  • Open Access.

Changing paradigms in management of inflammatory bowel disease

Mao, Ren, Magro, Fernando

Editorial Material. 10.1002/ueg2.12347. 2022

  • Open Access.

Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations

Schreiber, S; (...); Peyrin-Biroulet, L

Article. 10.1093/ecco-jcc/jjad130. 2023

  • Open Access.

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective

Parigi, TL; (...); Peyrin-Biroulet, L

Review. 10.1002/ueg2.12671. 2024

  • Open Access.

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review

Caron, B; (...); Peyrin-Biroulet, L

Review. 10.1002/ueg2.12283. 2022

  • Open Access.

Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper

Feakins, R; (...); Rosini, F

Article. 10.1093/ecco-jcc/jjad142. 2023

  • Open Access.

Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper

Rosini, F.; (...); Svrcek, M.

Meeting Abstract. 2024


Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis

Rubin, David T.; (...); Peyrin-Biroulet, Laurent

Article. 10.1093/ibd/izae204. 2024


Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites

Peyrin-Biroulet, L; (...); Kubassova, O

Meeting Abstract. 2023


DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES

Rubin, David T.; (...); Kubassova, Olga

Meeting Abstract. 2023


Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study (vol 12, pg 1104, 2021)

Charbit-Henrion, F; (...); Cerf-Bensussan, N

Correction. 10.1093/ecco-jcc/jjaa164. 2021

  • Open Access.

Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey

Parigi, TL; (...); Danese, S

Letter. 10.1016/S2468-1253(22)00085-1. 2022


Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting

Parigi, TL; (...); Danese, S

Review. 10.1016/S2468-1253(23)00154-1. 2023


Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions

Gomes, SF; (...); Magro, F

Article. 10.1515/cclm-2023-0139. 2023


Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus

D'Amico, F; (...); Danese, S

Review. 10.1093/ibd/izad159. 2023


Dose optimisation for Loss of Response to Vedolizumab - Pharmacokinetics and Immune Mechanisms

Ungar, B; (...); Ben Horin, S

Article. 10.1093/ecco-jcc/jjab067. 2021


Drug Prescribing Analysis: The Burden Of Orphan Drugs In A Tertiary Hospital Budget

Lopes, Diogo Jose; (...); Reina-Couto, Marta

Meeting Abstract. 2023


Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials

Magro, FERNANDO; (...); Feagan, Brian G.

Meeting Abstract. 2023


EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS

Magro, FERNANDO; (...); Peyrin-Biroulet, Laurent

Meeting Abstract. 2023


EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS

Magro, F.; (...); Daperno, M.

Meeting Abstract. 2024


ECCO Governing Board European Crohn's and Colitis Organisation - ECCO, Ungargasse 6/13, A-1030 Vienna, Austria

Peyrin-Biroulet, Laurent; (...); Armuzzi, Alessandro

Letter. 10.1093/ecco-jcc/jjab225. 2022

  • Open Access.

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

Kucharzik, T; (...); Vavricka, S

Editorial Material. 10.1093/ecco-jcc/jjab052. 2021

  • Open Access.

ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology

Magro, F; (...); Feakins, R

Article. 10.1093/ecco-jcc/jjac006. 2022

  • Open Access.

Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study

Estevinho, MM, Magro, F

Editorial Material. 10.1111/apt.17543. 2023

  • Open Access.

Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial

Danese, S; (...); Peyrin-Biroulet, L

Meeting Abstract. 10.1093/ecco-jcc/jjab075.034. 2021

  • Open Access.

Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)

Cosme, D., Soares-da-Silva, P., Magro, F.

Correction. 10.1152/ajpgi.00139.2023_COR. 2023


Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells

Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando

Article. 10.1152/ajpgi.00139.2022. 2022


EFFECT OF UPADACITINIB ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE IN THE PHASE 3, U-EXCEL, U-EXCEED, AND U-ENDURE STUDIES

Vermeire, Severine; (...); Peyrin-Biroulet, Laurent

Meeting Abstract. 2023


Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies

Vermeire, S.; (...); Peyrin-Biroulet, L.

Meeting Abstract. 2023


Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Albshesh, A; (...); Kopylov, U

Article. 10.3390/jcm10132914. 2021

  • Open Access.

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Magro, Fernando; (...); Reinisch, Walter

Article. 10.1016/j.cgh.2023.11.010. 2024

  • Open Access.

Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials

Estevinho, M. M.; (...); Magro, F.

Meeting Abstract. 2024


Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension

D'Haens, G.; (...); Blumenstein, I.

Meeting Abstract. 2024


Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial

Peyrin-Biroulet, L; (...); Danese, S

Meeting Abstract. 2022


EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN'S DISEASE: RESULTS FROM THE STARDUST TRIAL

Peyrin-Biroulet, Laurent; (...); Danese, Silvio

Meeting Abstract. 2022


Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials

Loftus, E; (...); Lichtenstein, G

Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023

  • Open Access.

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

Guillo, L; (...); Peyrin-Biroulet, L

Review. 10.1016/S2468-1253(21)00297-1. 2022

  • Open Access.

Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis

Estevinho, Maria Manuela, Magro, Fernando

Letter. 10.1016/j.cgh.2021.08.003. 2022

  • Open Access.

Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review (vol 14, pg 688, 2020)

Magro, F; (...); Peyrin-Biroulet, L

Correction. 2021


Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease

Pinto Lopes, P; (...); Magro, F.

Article. 10.14309/ctg.0000000000000320. 2021

  • Open Access.

Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue

De Sousa, HT, Gullo, I, Magro, FERNANDO

Letter. 10.1016/j.cgh.2022.06.023. 2023

  • Open Access.

Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease

De Sousa, H. Tavares; (...); Magro, F.

Meeting Abstract. 2024


Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis

Magro, F; (...); Santiago, M

Review. 10.1002/ueg2.12366. 2023

  • Open Access.

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

Pai, Rish K.; (...); Magro, FERNANDO

Review. 10.1080/17474124.2024.2326838. 2024

  • Open Access.

Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease

Reinisch, W.; (...); Pai, R.

Meeting Abstract. 2022


Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy

Magro, F.; (...); Carneiro, F.

Article. 10.1016/j.cgh.2020.09.017. 2021

  • Open Access.

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study

Magro, F; (...); Dias, CC

Article. 10.1002/ueg2.12420. 2023

  • Open Access.

How to Evaluate Fibrosis in IBD?

de Sousa, HT, Magro, F

Review. 10.3390/diagnostics13132188. 2023

  • Open Access.

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Peyrin-Biroulet, L; (...); Beaugerie, L

Article. 10.1016/j.cgh.2022.09.018. 2023

  • Open Access.

Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype

de Sousa, HT; (...); Magro, F

Article. 10.14309/ctg.0000000000000330. 2021

  • Open Access.

Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis

Roseira, Joana; (...); Magro, Fernando

Review. 10.1093/ibd/izac203. 2023


Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn's disease

Pai, Rish; (...); Dhesi, Endip

Meeting Abstract. 10.1136/gutjnl-2023-BSG.370. 2023


Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease

Pai, R.; (...); Magro, F.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.519. 2021


Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease

Pai, Rish; (...); Magro, FERNANDO

Meeting Abstract. 2021


Impact of mirikizumab therapy on histological measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease

Leong, R.; (...); Magro, F.

Meeting Abstract. 2022


Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Solitano, Virginia; (...); Danese, Silvio

Review. 10.1016/j.autrev.2023.103504. 2024

  • Open Access.

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?

Santiago, M; (...); Magro, F

Article. 10.14309/ctg.0000000000000481. 2022

  • Open Access.

Inflammation of the appendix in ulcerative colitis - Does it have a predictive value?

Magro, F, Estevinho, MM, Feakins, R

Editorial Material. 10.1002/ueg2.12181. 2021

  • Open Access.

Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce (vol 14, pg s798, 2020)

Magro, F.; (...); Peyrin-Biroulet, L.

Correction. 2021


Infrared furnace for in situ neutron single-crystal diffraction studies in controlled gas atmospheres at high temperatures

Magro, FERNANDO; (...); Paulus, Werner

Article. 10.1107/S1600576721003198. 2021


Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis

Ferreira-Duarte, M; (...); Morato, M

Article. 10.3390/ijms22094836. 2021

  • Open Access.

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients

Caron, B; (...); Peyrin-Biroulet, L

Review. 10.3390/medicina59010183. 2023

  • Open Access.

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

D'Amico, F; (...); Peyrin-Biroulet, L

Article. 10.1002/ueg2.12069. 2021

  • Open Access.

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

Olivera, PA; (...); Peyrin-Biroulet, L

Article. 10.1038/s41575-021-00492-8. 2021

  • Open Access.

Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis

Poenariu, Ioan Sabin; (...); Estevinho, Maria Manuela

Article. 10.3390/biomedicines11123137. 2023

  • Open Access.

IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

Caron, B; (...); Peyrin-Biroulet, L

Article. 10.1016/j.cgh.2022.02.032. 2022

  • Open Access.

iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

D'Amico, Ferdinando; (...); Danese, Silvio

Review. 10.3390/jcm12031142. 2023

  • Open Access.

Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results

D'Amico, F.; (...); Dignass, A.

Meeting Abstract. 2024


Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells

Cosme, D, soares-da-silva, p, Magro, F

Article. 10.1152/ajpcell.00208.2022. 2023


Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?

Magro, Fernando, Estevinho, Maria Manuela, Valois, Andre

Article. 10.1093/jcag/gwad034. 2023

  • Open Access.

Microbiota therapeutics for inflammatory bowel disease: the way forward

Bethlehem, Lukas; (...); Colombel, Jean-Frederic

Article. 10.1016/S2468-1253(23)00441-7. 2024

  • Open Access.

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Louis, E; (...); Travis, SP

Article. 10.1136/bmjgast-2021-000853. 2022

  • Open Access.

Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib

Magro, F.; (...); Reinisch, W.

Meeting Abstract. 2024


Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

Dignass, Axel U.; (...); Travis, Simon P. L.

Article. 10.1080/00365521.2021.2015801. 2022

  • Open Access.

Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients

Fernandes, BM; (...); Bernardes, J.

Article. 2022


Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients

Fernandes, B. M.; (...); Bernardes, M.

Article. 2022


Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?

Temido, Maria Jose; (...); Peyrin-Biroulet, Laurent

Editorial Material. 10.1093/ecco-jcc/jjae136. 2024

  • Open Access.

Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis

Estevinho, Maria Manuela; (...); Magro, Fernando

Review. 10.1111/apt.18315. 2024


Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Olivera, PA; (...); Peyrin-Biroulet, L

Review. 10.1093/ecco-jcc/jjac133. 2023


Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Schreiber, S; (...); Reinisch, W

Review. 10.1007/s12325-021-01990-6. 2022

  • Open Access.

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022)

Schreiber, S; (...); Reinisch, W

Correction. 10.1007/s12325-022-02082-9. 2022

  • Open Access.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

D'Haens, Geert R.; (...); Peyrin-Biroulet, Laurent

Meeting Abstract. 2021


Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years

Imbrizi, M, Magro, F, Coy, CSR

Review. 10.3390/ph16091272. 2023

  • Open Access.

Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project

Martins, A; (...); de Abreu, CMF

Meeting Abstract. 2023


Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

D'Amico, F; (...); Danese, S

Review. 10.1093/ecco-jcc/jjab206. 2022

  • Open Access.

Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review

Cosme, D; (...); Magro, F

Review. 10.1152/ajpcell.00393.2020. 2021

  • Open Access.

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

D'Amico, F; (...); Danese, S

Article. 10.3390/jcm12196350. 2023

  • Open Access.

Practical management of mild-to-moderate ulcerative colitis: an international expert consensus

D'Amico, Ferdinando; (...); Danese, Silvio

Review. 10.1080/17474124.2024.2397650. 2024

  • Open Access.

Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus

Fantini, Massimo Claudio; (...); Ghosh, Subrata

Article. 10.1093/ecco-jcc/jjae026. 2024

  • Open Access.

Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus

Fantini, M. C.; (...); Ghosh, S.

Meeting Abstract. 2024


Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus

Olivera, Pablo A.; (...); Peyrin-Biroulet, Laurent

Article. 10.1016/j.dld.2024.03.010. 2024

  • Open Access.

Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis

Fernandes, S. R.; (...); Magro, F.

Meeting Abstract. 2024


Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis

Fernandes, SR; (...); Magro, F

Article. 10.1093/ibd/izad272. 2023


Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study

Dignass, A.; (...); Leitner, C.

Meeting Abstract. 2024


Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study

D'Amico, Ferdinando; (...); Dignass, Axel

Article. 10.1002/ueg2.12572. 2024

  • Open Access.

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease

Magalhaes, Diogo; (...); GEDII

Review. 10.1177/17562848231155987. 2023

  • Open Access.

Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!

Magro, F, Estevinho, MM

Editorial Material. 10.1002/ueg2.12432. 2023

  • Open Access.

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

Magro, F; (...); Peyrin-Biroulet, L

Article. 10.1093/ecco-jcc/jjad050. 2023

  • Open Access.

Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial

Vermeire, S.; (...); Bolca, S.

Meeting Abstract. 2024


Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language

Roseira, Joana; (...); Magro, Fernando

Article. 10.1186/s12955-021-01698-9. 2021

  • Open Access.

Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years

Magro, F; (...); Dias, CC

Article. 10.1016/j.cgh.2021.12.004. 2022

  • Open Access.

SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS

Magro, FERNANDO; (...); Dias, Camila

Meeting Abstract. 2022


The degree of bowel remission predicts phenotype progression in Crohn's disease

Fernandes, Samuel Raimundo; (...); Magro, FERNANDO

Article. 10.1002/ueg2.12581. 2024

  • Open Access.

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

Cheon, Jae Hee; (...); Travis, Simon Pl

Article. 10.5217/ir.2022.00006. 2022

  • Open Access.

The importance of a Clinical Pharmacology Unit to a Pharmacy and Therapeutics Committee, in a tertiary hospital

Borges-Carneiro, Filipa; (...); Magro, FERNANDO

Meeting Abstract. 2023


The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Magro, F.; (...); Santiago, M.

Meeting Abstract. 2024


The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients

Magro, Fernando; (...); Santiago, Mafalda

Article. 10.1093/ecco-jcc/jjae014. 2024


The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review

Santiago, M; (...); Magro, F

Review. 10.1093/ibd/izab334. 2022


The Process of Developing a Disease Activity Index in Microscopic Colitis

Lesnovska, Katarina Pihl; (...); Hjortswang, Henrik

Article. 10.1093/ecco-jcc/jjab170. 2022

  • Open Access.

Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab

Sousa, P; (...); Magro, F

Article. 10.1016/j.dld.2023.10.027. 2024

  • Open Access.

Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease

Sousa, P; (...); Magro, F

Article. 10.1016/j.dld.2021.05.038. 2021

  • Open Access.

Thiopurines: use them or lose them? Results of an international survey

Sousa, P. C.; (...); Magro, F.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.531. 2021

  • Open Access.

Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease

Fernandes, SR; (...); Magro, F

Article. 10.1002/ueg2.12497. 2023

  • Open Access.

Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties (vol 14, pg 743, 2020)

de Sousa, HT; (...); Magro, F

Correction. 2021


Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease

Fernandes, S. R.; (...); Magro, F.

Meeting Abstract. 2024


Transmural remission improves clinical outcomes up to 5 years in Crohn's disease

Fernandes, Samuel Raimundo; (...); Magro, FERNANDO

Article. 10.1002/ueg2.12356. 2023

  • Open Access.

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Danese, S; (...); Peyrin-Biroulet, L

Article. 10.1016/S2468-1253(21)00474-X. 2022

  • Open Access.

UEG journal: The voice of European Gastroenterology

Meining, Alexander G., Magro, Fernando, Drenth, Joost P. H.

Editorial Material. 10.1002/ueg2.12264. 2022

  • Open Access.

Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study

D'Amico, Ferdinando; (...); Danese, Silvio

Article. 10.1002/ueg2.12288. 2022

  • Open Access.

Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results

Dignass, A.; (...); Magro, F.

Meeting Abstract. 2024


USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Danese, Silvio; (...); Peyrin-Biroulet, Laurent

Meeting Abstract. 2021


Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial

Panés, J; (...); Dignass, A

Article. 10.1002/ueg2.12384. 2023

  • Open Access.

Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial

Danese, S; (...); Peyrin-Biroulet, L

Meeting Abstract. 10.1093/ecco-jcc/jjab076.425. 2021

  • Open Access.

Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases

Abreu, C; (...); Magro, F

Article. 10.1097/MEG.0000000000002589. 2023

  • Open Access.

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis (vol 14, pg 1066, 2020)

Vermeire, Severine; (...); Danese, Silvio

Correction. 2021


Viable Mycobacterium avium subsp. paratuberculosis Colonizes Peripheral Blood of Inflammatory Bowel Disease Patients

Estevinho, MM; (...); Sarmento, A

Article. 10.3390/microorganisms11061520. 2023

  • Open Access.

Burden Of Inflammatory Bowel Disease In Portugal

Tese de doutoramento

Colaboradores: Fernando José Magro Dias


Composite Outcomes In Observational Studies Of Crohn?S Disease: A Systematic Review And Meta-Analysis

Dissertação de Mestrado

Colaboradores: Fernando José Magro Dias


Composite Outcomes In Observational Studies Of Crohn’s Disease: A Systematic Review And Meta-Analysis

Projeto de fim de curso

Colaboradores: Fernando José Magro Dias


Histologic Features Of Colon Biopsies (Geboes Score) Associated With Progression Of Ulcerative Colitis For The First 36 Months After Biopsy

Projeto de fim de curso

Colaboradores: Fernando José Magro Dias


Histologic Features Of Colon Biopsies (Geboes Score) Associated With Progression Of Ulcerative Colitis For The First 36 Months After Biopsy

Dissertação de Mestrado

Colaboradores: Fernando José Magro Dias


Isolated Ulceration Of Crohn?S Anastomosis

Dissertação de Mestrado

Colaboradores: Fernando José Magro Dias


Isolated Ulceration Of Crohn’s Anastomosis

Projeto de fim de curso

Colaboradores: Fernando José Magro Dias


Partilhar